Drug Of Abuse Rapid Screen Tests

Disclaimer: This assay provides preliminary analytical test results. A definitive conclusion should only be made by a qualified physician based on further relevant clinical and laboratory findings and evaluations.

iCARE DOA Rapid Screen tests employ an unique monoclonal antibodies to selectively identify specific drugs of abuse (DOA) and the corresponding metabolites in urine samples with a high degree of sensitivity and specificity. As manufacturers our DOA rapid tests are lateral flow, qualitative quick check devices based on the drug-competitive inhibition immunoassay.
As exporters and bulk suppliers of Rapid screen tests, for all our DOA screening test devices, the cut off concentration for specific drug of abuse (DOA) and its metabolites has been developed at the concentration standards set by NIDA (the National Institute on Drug Abuse of USA) for the qualitative detection of corresponding drugs in human urine specimens.

DOA urine screening tests are highly sensitive and specific.
iCARE DOA testing results are read visually without the need for other instrumentation.
No extra reagent is needed for these DOA urine screening tests.
iCARE DOA testing kits are used to screen urine specimens for the presence of corresponding drug of abuse and its metabolites.
iCARE DOA testing devices are available in strip, cassette and multi-drug panel styles.
2, 4, 5, 6 and 10 multi-drug test panels are available (Combination of tests are designed specifically to your requirements).

Jal Medical as a wholesale supplier of diagnostic kits, bulk supply various diagnostic products like drug of abuse test kit to different health care units and other facilities.

FAQs About Drug of Abuse Rapid Screen Tests

1. What is the iCARE DOA-5 – DRUGS OF ABUSE 5 PANEL TEST?

The iCARE DOA-5 is a state-of-the-art drug testing kit designed to detect the presence of five commonly abused substances in a single panel test. This includes tests for marijuana, cocaine, amphetamine, methamphetamine, and opiates. It provides a reliable and rapid screening solution for identifying potential drug use.

The iCARE DOA-5 panel test detects five major substances: marijuana, cocaine, amphetamine, methamphetamine, and opiates.
This test offers a quick and efficient screening process, providing results within a short timeframe.
The iCARE DOA-5 is a reliable tool for identifying potential drug use in various settings, ensuring a comprehensive approach to substance abuse detection.

2. How does the iCARE DOA-7 – DRUGS OF ABUSE 7 PANEL TEST differ from the DOA-5?

The iCARE DOA-7 expands on the capabilities of the DOA-5 by detecting an additional two substances, making it a seven-panel drug testing solution. It includes tests for benzodiazepines and barbiturates, providing a more comprehensive analysis of potential drug use.

The iCARE DOA-7 panel test identifies seven substances, including marijuana, cocaine, amphetamine, methamphetamine, opiates, benzodiazepines, and barbiturates.
This extended panel allows for a more thorough examination of potential drug use, catering to a wider range of substances.
With the iCARE DOA-7, users can benefit from a holistic approach to drug testing, ensuring a more detailed and accurate screening process.

3. What substances does the iCARE DOA-14 – DRUGS OF ABUSE 14 PANEL TEST screen for?

The iCARE DOA-14 is a comprehensive drug testing solution designed to detect the presence of 14 different substances in a single panel test. This advanced kit covers a broad spectrum of drugs, providing a thorough examination of potential substance abuse.

The iCARE DOA-14 panel test screens for 14 substances, including marijuana, cocaine, amphetamine, methamphetamine, opiates, benzodiazepines, barbiturates, phencyclidine (PCP), ecstasy, tricyclic antidepressants, methadone, propoxyphene, buprenorphine, and oxycodone.
This extensive panel ensures a comprehensive analysis, making it a suitable choice for various settings where a broad approach to drug testing is essential.
The iCARE DOA-14 offers a reliable and efficient solution for identifying multiple substances, contributing to a more nuanced understanding of potential drug use.

4. What Drug Of Abuse Rapid Screen Test Kits does Jal Medical offer for Central Asia?

Jal Medical offers a comprehensive range of Drug Of Abuse Rapid Screen Test Kits tailored for Central Asia, covering countries like Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan.

Jal Medical provides kits for detecting a variety of substances, including opioids, cannabinoids, amphetamines, cocaine, and benzodiazepines.
The kits are designed to meet the specific needs of Central Asian healthcare settings, ensuring accurate and swift results.
Each test kit comes with clear instructions, making them user-friendly for healthcare professionals in the region.

5. Can Jal Medical Supplies iCARE drug of abuse test kits to all African countries?

Yes, Jal Medical Supplies can facilitate the shipment of iCARE drug tests to various African countries, including Nigeria, Ethiopia, Egypt, DR Congo, Tanzania, South Africa, Kenya, Uganda, Sudan, Algeria, Morocco, Angola, Ghana, Mozambique, Madagascar, Ivory Coast, Cameroon, Niger, Mali, Burkina Faso, Malawi, Zambia, Chad, Somalia, Senegal, Zimbabwe, Guinea, Rwanda and many more.

6. How do the iCARE DOA panel test kits benefit Caribbean countries?

The iCARE DOA panel test kits hold significant benefits for Caribbean countries, including Anguilla, Antigua and Barbuda, Aruba, the Bahamas, Barbados, Belize, Bermuda, British Virgin Islands, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guyana, Jamaica, Haiti, Montserrat, Netherlands Antilles, and Puerto Rico.

Three most important information:

Customized for Regional Needs: Tailored to the specific requirements of Caribbean countries, the iCARE DOA test is an effective solution that addresses the unique challenges and considerations of the region.
Compliance with Standards: The test adheres to international standards, ensuring that it meets the regulatory requirements of Caribbean nations. This compliance enhances its reliability and acceptance in diverse applications.
Contributing to Public Health: By enabling accurate drug screening, the iCARE DOA test plays a vital role in safeguarding public health and promoting a safer and more productive environment in Caribbean communities.